VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
Currently, Viking Therapeutics does not have any approved products in its portfolio. Hence, it it yet to generate revenues.
More on VKTX's Q2 Earnings
Research and development (R&D) expenses amounted to $60.2 million, compared with $23.8 million incurred in the year-ago period. This significant increase was primarily due to higher costs associated with clinical studies and manufacturing for the company's drug candidates, as well as increased employee-related expenses.
General and administrative expenses amounted to $14.4 million, up 40% year over year, primarily due to higher employee-related expenses.
Shares of VKTX were down 8% in after-market trading yesterday, likely due to a wider-than-expected loss incurred in the quarter on higher operating expenses.
The stock has outperformed the industry so far this year, as seen in the chart below.
Image Source: Zacks Investment Research
As of June 30, 2025, Viking Therapeutics had cash, cash equivalents and short-term investments worth $808 million compared with $852 million as of March 31, 2025.
2025 Guidance
While Viking did not provide hard numbers, it indicated on the conference call that R&D expenses are expected to rise sequentially by approximately 25% to one-third in the third and fourth quarters of 2025 compared with the second quarter.
VKTX's Pipeline Updates
Viking Therapeutics is one of the few biotech stocks that has shown immense potential in the obesity space. It is developing VK2735, an investigational novel dual GLP-1 and GIP receptor agonist, in different clinical studies as oral and subcutaneous (SC) versions for treating obesity.
Last month, Viking Therapeutics started the phase III VANQUISH program to evaluate VK2735 SC in adult patients with or without type II diabetes (T2D) for 78 weeks. The program consists of two late-stage studies — the VANQUISH-1 study will enroll obese adults with at least one weight-related co-morbid condition, while the VANQUISH-2 study will enroll obese or overweight adults with T2D. VKTX is targeting enrollment of about 4,500 participants for the VANQUISH-1 study and around 1,100 for the VANQUISH-2 study.
Viking is also evaluating the oral formulation of VK2735 in the ongoing phase II VENTURE-Oral Dosing study, which spans over 13 weeks. Data from this study is expected before this year's end.
Additionally, the company reiterated plans to file an investigational new drug application with the FDA in the fourth quarter of 2025 to advance an internally developed amylin agonist program to clinical development for treating obesity.
VKTX's Zacks Rank
Viking currently carries a Zacks Rank #3 (Hold).
Viking Therapeutics, Inc. Price
Viking Therapeutics, Inc. price | Viking Therapeutics, Inc. Quote
Our Key Picks Among Biotech Stocks
Some better-ranked stocks from the sector are Akero Therapeutics AKRO, Amarin Corporation AMRN and Agenus AGEN. While AMRN and AKRO sport a Zacks Rank #1 (Strong Buy) each at present, AGEN carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
In the past 90 days, loss per share estimates for Akero's 2025 have improved from $4.08 to $3.93. Loss per share estimates for 2026 have narrowed from $4.30 to $4.27 during the same period. AKRO stock has surged 86% year to date.
Akero's earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 48.90%.
In the past 90 days, loss per share estimates for Amarin's 2025 have improved from $4.60 to $2.30. Loss per share estimates for 2026 have narrowed from $3.87 to $1.50 during the same period. AMRN stock has surged 61% year to date.
Amarin's earnings beat estimates in two of the trailing four quarters, met the mark once and missed the mark on another occasion, delivering an average surprise of 29.11%.
In the past 90 days, Agenus' bottom-line estimates for 2025 have significantly improved from a loss of $3.46 per share to earnings of $1.56. During the same timeframe, estimates for 2026 loss per share have narrowed from $3.91 to $1.99. AGEN stock has soared 122% so far this year.
Agenus' earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average negative surprise of 22.71%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Agenus Inc. (AGEN) : Free Stock Analysis Report
Amarin Corporation PLC (AMRN) : Free Stock Analysis Report
Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report
Akero Therapeutics, Inc. (AKRO) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
1&1's (ETR:1U1) Returns On Capital Not Reflecting Well On The Business
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and find a company with returns on capital employed (ROCE) that are increasing, in conjunction with a growing amount of capital employed. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. Although, when we looked at 1&1 (ETR:1U1), it didn't seem to tick all of these boxes. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Understanding Return On Capital Employed (ROCE) For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. The formula for this calculation on 1&1 is: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.07 = €546m ÷ (€8.4b - €680m) (Based on the trailing twelve months to March 2025). Therefore, 1&1 has an ROCE of 7.0%. In absolute terms, that's a low return and it also under-performs the Wireless Telecom industry average of 9.0%. Check out our latest analysis for 1&1 Above you can see how the current ROCE for 1&1 compares to its prior returns on capital, but there's only so much you can tell from the past. If you're interested, you can view the analysts predictions in our free analyst report for 1&1 . The Trend Of ROCE On the surface, the trend of ROCE at 1&1 doesn't inspire confidence. To be more specific, ROCE has fallen from 13% over the last five years. Meanwhile, the business is utilizing more capital but this hasn't moved the needle much in terms of sales in the past 12 months, so this could reflect longer term investments. It's worth keeping an eye on the company's earnings from here on to see if these investments do end up contributing to the bottom line. The Bottom Line On 1&1's ROCE To conclude, we've found that 1&1 is reinvesting in the business, but returns have been falling. Since the stock has declined 16% over the last five years, investors may not be too optimistic on this trend improving either. All in all, the inherent trends aren't typical of multi-baggers, so if that's what you're after, we think you might have more luck elsewhere. One more thing to note, we've identified 2 warning signs with 1&1 and understanding these should be part of your investment process. While 1&1 isn't earning the highest return, check out this free list of companies that are earning high returns on equity with solid balance sheets. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 hours ago
- Yahoo
1&1's (ETR:1U1) Returns On Capital Not Reflecting Well On The Business
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and find a company with returns on capital employed (ROCE) that are increasing, in conjunction with a growing amount of capital employed. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. Although, when we looked at 1&1 (ETR:1U1), it didn't seem to tick all of these boxes. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Understanding Return On Capital Employed (ROCE) For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. The formula for this calculation on 1&1 is: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.07 = €546m ÷ (€8.4b - €680m) (Based on the trailing twelve months to March 2025). Therefore, 1&1 has an ROCE of 7.0%. In absolute terms, that's a low return and it also under-performs the Wireless Telecom industry average of 9.0%. Check out our latest analysis for 1&1 Above you can see how the current ROCE for 1&1 compares to its prior returns on capital, but there's only so much you can tell from the past. If you're interested, you can view the analysts predictions in our free analyst report for 1&1 . The Trend Of ROCE On the surface, the trend of ROCE at 1&1 doesn't inspire confidence. To be more specific, ROCE has fallen from 13% over the last five years. Meanwhile, the business is utilizing more capital but this hasn't moved the needle much in terms of sales in the past 12 months, so this could reflect longer term investments. It's worth keeping an eye on the company's earnings from here on to see if these investments do end up contributing to the bottom line. The Bottom Line On 1&1's ROCE To conclude, we've found that 1&1 is reinvesting in the business, but returns have been falling. Since the stock has declined 16% over the last five years, investors may not be too optimistic on this trend improving either. All in all, the inherent trends aren't typical of multi-baggers, so if that's what you're after, we think you might have more luck elsewhere. One more thing to note, we've identified 2 warning signs with 1&1 and understanding these should be part of your investment process. While 1&1 isn't earning the highest return, check out this free list of companies that are earning high returns on equity with solid balance sheets. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
2 days ago
- Yahoo
Why Oscar Health, Inc. (OSCR) Outpaced the Stock Market Today
In the latest trading session, Oscar Health, Inc. (OSCR) closed at $14.45, marking a +1.76% move from the previous day. This change outpaced the S&P 500's 0.4% gain on the day. Meanwhile, the Dow gained 0.47%, and the Nasdaq, a tech-heavy index, added 0.24%. The company's stock has dropped by 30.66% in the past month, falling short of the Finance sector's gain of 3.3% and the S&P 500's gain of 4.61%. The upcoming earnings release of Oscar Health, Inc. will be of great interest to investors. The company's earnings report is expected on August 6, 2025. The company is expected to report EPS of -$0.59, down 395% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $2.89 billion, up 30.15% from the year-ago period. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.68 per share and revenue of $11.87 billion. These totals would mark changes of -780% and +29.34%, respectively, from last year. Investors might also notice recent changes to analyst estimates for Oscar Health, Inc. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 211.41% downward. Right now, Oscar Health, Inc. possesses a Zacks Rank of #4 (Sell). The Insurance - Multi line industry is part of the Finance sector. This group has a Zacks Industry Rank of 159, putting it in the bottom 36% of all 250+ industries. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Keep in mind to rely on to watch all these stock-impacting metrics, and more, in the succeeding trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Oscar Health, Inc. (OSCR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
